Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

A Breast Cancer Test That Saves Lives

Posted : Tue, 03 Nov 2009 10:01:28 GMT
Author : Provista
Category : Press Release
News Alerts by Email ( click here )
News | Home
The BT Test(R) - A Simple Blood Test for the Early Detection of Breast Cancer PHOENIX, Nov. 3

PHOENIX, Nov. 3 /PRNewswire/ -- A healthy 44-year-old woman will celebrate many future birthdays thanks to the efforts of Dr. Keri Sweeten and a new blood test for breast cancer.

Dr. Sweeten, a board-certified gynecologist and Fellow of the American College of Obstetricians and Gynecologists, recently incorporated the Provista Life Science BT TestĀ®, a blood test for the detection of breast cancer, into her patient care practice. Sweeten noted a case where a 44-year-old patient called to schedule her annual mammogram, and in advance of the mammogram Sweeten ordered the BT Test. When her patient's BT ScoreĀ® came back high, indicating an increased likelihood of the presence of breast cancer, she changed the order for her patient's routine screening mammogram to a diagnostic bilateral mammogram.

A diagnostic mammogram is an enhanced radiology procedure that increases the number and angles of breast imaging views with increased magnification of those views. Using this procedure, the radiologist was able to locate a deep, very small clustering of suspicious looking cells in the patient's left breast. A biopsy was recommended, performed and the subsequent pathologist's report came back with a confirmed diagnosis of cancer. Surgery was scheduled two weeks later and the cancerous growth removed.

"My patient is a young woman with dense breast tissue where the sensitivity of digital and film mammography is known to be limited, but is still considered the standard of care. Had it not been for the BT Test, we might not have caught her cancer," said Sweeten. "My patient's first reply to me was, 'You saved my life.' I'm not sure much more needs to be said."

The BT Test, or the Biomarker Translation Test, is a CLIA compliant laboratory test developed by Phoenix-based Provista Life Sciences. The test analyzes blood for changes in multiple serum-based protein biomarkers levels that are associated with the underlying pathology of breast cancer. The individual test results, along with a brief patient-specific medical profile, are processed through a proprietary data analysis procedure to generate a single numeric value called the BT Score, which is indicative of the presence or absence of breast cancer.

"The BT Test was designed to provide healthcare providers with another 'tool in their toolbox' that can be used as a complement with current imaging technologies in the fight to detect this devastating disease as early as possible," said William J. Gartner, CEO and President of Provista. "For Dr. Sweeten's patient, the BT Test played a role in detecting her breast cancer and we are proud of that."

The BT Test is currently available in 41 states, 27 of which are considered direct-to-consumer states where a physician's prescription is not required. The BT Test can be ordered through a women's primary healthcare provider or online. Once the sample is collected and tested, the results are sent to the patient and/or their designated primary care physician. A complete list of local Phoenix area providers is also available on the Provista Web site: www.provistals.com. To find out more about the BT Test and how it can be ordered visit their Web site or call 602-224-5500

About Provista Life Sciences
Provista Life Sciences is a biotechnology diagnostic development and commercialization organization that provides the scientific and operating management resources to rapidly advance the development and introduction of novel diagnostic technologies into the domestic and global marketplace. For more information, visit the company's Web site at www.ProvistaLS.com or call 602-224-5500

Dr. Keri Sweeten, M.D. - Understanding Women
Dr. Sweeten founded "Understanding Women" in 2003, a practice dedicated to giving women a single place to receive their most sensitive and critical healthcare needs in an understanding and caring environment. Dr. Sweeten is a board-certified gynecologist, a Fellow of the American College of Obstetricians and Gynecologists, Vice President of the Phoenix OB/Gyn Society, a member of the Society of Laparoendoscopic Surgeons, the American Academy of Cosmetic Surgeons, American Society of Lasers in Medicine and Surgery and the American Urogynecologic Society. For more information, visit her website at www.drsweeten.com or call 602-393-0661.

    MEDIA CONTACTS:
    The Lavidge Company
    480.998.2600
    Greg Sexton ext. 555
    gsexton@lavidge.com
    Anne Robertson ext. 537
    arobertson@lavidge.com

SOURCE Provista


Copyright © 2008 PR Newswire. All rights reserved.

Share/Save/Bookmark



Related News

AU Optronics Honored with 2009 / 2010 Ocean Tomo 300(R) Patent Index
HSINCHU, Taiwan, Nov. 26 /PRNewswire-Asia/ -- AU Optronics Corp. ("AUO" or the "Company") (TAIEX: 2409; NYSE: AUO) announced today that it is honored with the 2009 / 2010 Ocean Tomo 300(R) Patent Index. It indicates high recognition fo...

Katarina Bylund Appointed New Senior Vice President of Group Staff Unit Reporting at Skanska
STOCKHOLM - Regulatory News: Katarina Bylund has been appointed new Senior Vice President Reporting at Skanska (STO:SKAB) from April 1, 2010. She will succeed Mats Moberg, who will retire at the end of the first quarter of 2010. From January, Katarina B

Naspers Limited Today Announced Results for the Six Months Ended 30 September 2009
CAPE TOWN - Naspers (JSE:NPN) (LSE:NPSN) today reported a 6% increase in revenue to R13,5 billion for the six months ended 30 September 2009. Operating profit (before amortisation and other gains and losses) grew by 19% to R2,8 billion. Core headline earnings were up t

Galapagos receives EUREKA innovation label and OSEO funding
MECHELEN, BELGIUM -- 11/26/09 -- Mechelen, Belgium; 26 November 2009 - Galapagos NV (Euronext: GLPG) announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French gove..

TELEPERFORMANCE : Financial Meeting - November 26, 2009
PARIS -- 11/26/09 -- Objectives 2009 - Revenues +2.5% - Based on published data -1.3% - On a comparable basis* - EBITA** - excl. non-recurring items EUR 154 - 155 million 8.5% of revenues Outlook f..

New Zealand Beach Front Property Offers Global Currency Rate Bargains
Although the median price of the average New Zealand home has remained relatively stable since January, 2009 (1 April, 09 Bloomberg Report); the price decrease of 8% over the last year, and the NZ dollar decline of between 16 and 28 percent against the Euro and US currencies respectively duri...

Pedata RV Center Offers 3 Tips To RVing Fulltime
Pedata RV Center offers 3 tips that will make converting from a traditional home to a home on the road in a modern recreational vehicle smooth./I/P PPhoenix, AZ (Vocus) November 25, 2009 -- Pedata RV Center offers 3 tips to prospective fulltime RVers that will make the conversion from a...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.